🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/03/2004 | 10,47 | 10,88 | 10,15 | 10,17 | -3,33% | 6,97% | 761.300 |
| 09/03/2004 | 11,10 | 11,15 | 10,47 | 10,52 | -4,45% | 6,13% | 850.100 |
| 08/03/2004 | 11,47 | 11,50 | 10,84 | 11,01 | -2,65% | 5,75% | 592.200 |
| 05/03/2004 | 11,15 | 11,51 | 11,09 | 11,31 | -0,53% | 3,77% | 533.200 |
| 04/03/2004 | 10,97 | 11,40 | 10,97 | 11,37 | +2,43% | 3,92% | 673.200 |
| 03/03/2004 | 11,05 | 11,17 | 10,80 | 11,10 | -0,54% | 3,35% | 654.800 |
| 02/03/2004 | 10,96 | 11,23 | 10,91 | 11,16 | +1,73% | 2,92% | 775.100 |
| 01/03/2004 | 11,41 | 11,41 | 10,96 | 10,97 | -2,66% | 3,94% | 751.600 |
| 27/02/2004 | 11,51 | 11,57 | 11,12 | 11,27 | -0,18% | 3,91% | 846.500 |
| 26/02/2004 | 11,15 | 11,32 | 11,00 | 11,29 | +1,26% | 2,87% | 754.700 |
| 25/02/2004 | 11,00 | 11,31 | 10,80 | 11,15 | +1,36% | 4,64% | 1.143.900 |
| 24/02/2004 | 10,78 | 11,27 | 10,46 | 11,00 | +0,27% | 7,51% | 2.006.500 |
| 23/02/2004 | 12,20 | 12,20 | 10,90 | 10,97 | +7,44% | 10,66% | 10.771.000 |
| 20/02/2004 | 10,69 | 10,69 | 10,09 | 10,21 | -3,50% | 5,61% | 1.320.800 |
| 19/02/2004 | 11,05 | 11,32 | 10,49 | 10,58 | -3,02% | 7,51% | 801.600 |
| 18/02/2004 | 10,90 | 11,15 | 10,87 | 10,91 | +1,77% | 2,57% | 1.076.100 |
| 17/02/2004 | 10,26 | 10,90 | 10,26 | 10,72 | +3,98% | 6,24% | 1.468.400 |
| 13/02/2004 | 10,07 | 10,45 | 10,06 | 10,31 | +1,68% | 3,87% | 757.700 |
| 12/02/2004 | 10,17 | 10,35 | 10,05 | 10,14 | -0,39% | 2,95% | 639.200 |
| 11/02/2004 | 10,15 | 10,30 | 10,02 | 10,18 | +0,10% | 2,76% | 610.400 |
| 10/02/2004 | 9,80 | 10,26 | 9,70 | 10,17 | +0,20% | 5,71% | 808.000 |
| 09/02/2004 | 9,69 | 10,19 | 9,65 | 10,15 | +4,10% | 5,57% | 624.500 |
| 06/02/2004 | 9,55 | 9,77 | 9,48 | 9,75 | +1,25% | 3,04% | 622.400 |
| 05/02/2004 | 9,58 | 9,74 | 9,45 | 9,63 | +2,23% | 3,03% | 559.500 |
| 04/02/2004 | 9,64 | 9,74 | 9,40 | 9,42 | -3,88% | 3,53% | 919.600 |
| 03/02/2004 | 9,31 | 9,83 | 9,28 | 9,80 | +0,10% | 5,91% | 959.600 |
| 02/02/2004 | 9,76 | 10,09 | 9,72 | 9,79 | -1,21% | 3,79% | 846.700 |
| 30/01/2004 | 10,00 | 10,19 | 9,74 | 9,91 | -1,78% | 4,50% | 372.700 |
| 29/01/2004 | 10,09 | 10,20 | 9,69 | 10,09 | -0,39% | 5,05% | 527.600 |
| 28/01/2004 | 9,95 | 10,23 | 9,88 | 10,13 | +2,63% | 3,52% | 1.044.700 |